Renal Cell Carcinoma

Nivolumab plus ipilimumab improve survival in advanced renal cell carcinoma

1. Amongst patients with advanced renal-cell carcinoma and an intermediate or poor prognosis, nivolumab plus ipilimumab was superior to sunitinib alone in improving overall survival. 2. Though not statistically compared, there was a lower incidence of grade three or four adverse events with nivolumab plus ipilimumab, although more patients in the combination therapy arm stopped []

Relative Visceral Fat Area an Indicator of Mortality Risk for Women With RCC

Relative Visceral Fat Area an Indicator of Mortality Risk for Women With RCC

By

An evaluation of patients with clear cell renal cell carcinoma revealed greater risk of death for female patients with high relative visceral fat area (rVFA), highlighting the significance of metabolic differences between men and women.

Axitinib Plus Pembrolizumab Shows Promise in Treatment-Naïve Advanced RCC

Axitinib Plus Pembrolizumab Shows Promise in Treatment-Naïve Advanced RCC

By

Nonrandomized trial demonstrates tolerability and antitumor activity of a PD-1 checkpoint inhibitor plus a VEGF-TKI in patients with treatment-naïve advanced RCC.

Sex, Age Associated With Mortality Risk in Renal Cell Cancer Treated With VEGF-TKIs

Sex, Age Associated With Mortality Risk in Renal Cell Cancer Treated With VEGF-TKIs

By

Phase 3 study sought to assess the associations between adjuvant therapy with VEGF-tyrosine kinase inhibitors (TKIs) and benefit, sex, and age in patients with resected renal cell cancer.

Antibiotics May Reduce Treatment-Related Issues in Renal Cell Carcinoma

Antibiotics May Reduce Treatment-Related Issues in Renal Cell Carcinoma

By

Researchers evaluated the effect of antibiotics on treatment delays, interruptions, and dose reductions in patients with mRCC treated with a first-line VEGF-TKI and presented their results at the 2018 Genitourinary Cancers Symposium.

Indications for Cabozantinib in Advanced RCC Expanded to First-line Therapy

Indications for Cabozantinib in Advanced RCC Expanded to First-line Therapy

By

The FDA based its approval on data collected from the open-label, phase 2 CABOSUN study, for which researchers randomly assigned 157 patients with RCC to receive oral cabozantinib or sunitinib.

FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC

FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC

By

Combination therapy with lenvatinib and pembrolizumab is granted Breakthrough Therapy Designation for the treatment of advanced or metastatic renal cell carcinoma (RCC).

Patients Report Significant Fatigue with Sorafenib, Sunitinib in Renal Cell Carcinoma

Patients Report Significant Fatigue with Sorafenib, Sunitinib in Renal Cell Carcinoma

By

Although TKIs improve outcomes, they are still associated with toxicities common with cancer therapies, such as fatigue.

Practical Management of Adverse Events Associated With Cabozantinib Treatment in Patients With Renal-cell Carcinoma

Practical Management of Adverse Events Associated With Cabozantinib Treatment in Patients With Renal-cell Carcinoma

[OncoTargets and Therapy] This research reviews the management of the more common adverse events associated with cabozantinib treatment for patients with patients with advanced clear-cell renal-cell carcinoma.

Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer

Savolitinib Active, Tolerable in Subset of Advanced Papillary Renal Cell Cancer

By

Results of a phase 2 clinical trial of savolitinib, a highly selective small molecule inhibitor of c-Met, found the agent was active and tolerable in patients with Met-driven advanced or metastatic papillary renal cell carcinoma (PRCC).

Complete vs Incomplete Metastasectony for mRCC: Improved Survival, Decreased All-Cause Mortality

Complete vs Incomplete Metastasectony for mRCC: Improved Survival, Decreased All-Cause Mortality

By

Complete surgical metastasectomy correlated with increased survival in patients with metastatic renal cell carcinoma (mRCC) compared with incomplete surgical metastasectomy.

GUCS 2017: Early Immunotherapy Discontinuation in mRCC

GUCS 2017: Early Immunotherapy Discontinuation in mRCC

By

Patients with advanced renal cell carcinoma (RCC) who discontinued anti-PD-1/PD-L1 immunotherapy early may still achieve durable responses.

ABX May Impact Efficacy of Checkpoint Inhibitors in RCC

ABX May Impact Efficacy of Checkpoint Inhibitors in RCC

By

Patients with advanced kidney cancer received broad-spectrum antibiotics less than a month before initiating immune checkpoint inhibitor therapy.

Alternating Pazopanib and Everolimus Treatment Schedule Not Effective for RCC

Alternating Pazopanib and Everolimus Treatment Schedule Not Effective for RCC

By

Alternating treatment with pazopanib and everolimus failed to prolong progression-free survival compared with continuous pazopanib.

Prognostic role of pretreatment serum albumin in renal cell carcinoma: a systematic review and meta-analysis

Prognostic role of pretreatment serum albumin in renal cell carcinoma: a systematic review and meta-analysis

[OncoTargets and Therapy] This research examines the prognostic value of pretreatment serum albumin in RCC patients.

Adjuvant Girentuximab Not Effective for Renal Cell Carcinoma

Adjuvant Girentuximab Not Effective for Renal Cell Carcinoma

By

Phase 2 studies have demonstrated that girentuximab possesses activity with a manageable safety profile for patients with clear cell renal cell carcinoma; therefore, in a phase 3 trial, researchers evaluated its efficacy and safety as adjuvant monotherapy.

Clinical Use of Cabozantinib in the Treatment of Advanced Kidney Cancer: Efficacy, Safety, and Patient Selection

Clinical Use of Cabozantinib in the Treatment of Advanced Kidney Cancer: Efficacy, Safety, and Patient Selection

[OncoTargets and Therapy] This research We reviews the development of cabozantinib in advanced renal cell carcinoma and its role in the treatment landscape.

New Class of Drugs Shows Promise Against Kidney Cancer

New Class of Drugs Shows Promise Against Kidney Cancer

By

A new class of drugs, that interferes with processes that fuel cell growth, is more effective and better tolerated that the standard-of-care drug for clear cell renal cell carcinoma.

Study Evaluates Incidence of PD-1 Blockade-related Pneumonitis

By

Pneumonitis related to the use of PD-1 inhibitor therapy is higher among patients with NSCLC and RCC, and during combination therapy.

Biomarkers Predict Response to TKI Therapy for Metastatic Renal Cell Carcinoma

Biomarkers Predict Response to TKI Therapy for Metastatic Renal Cell Carcinoma

By

Presence of certain microRNAs (miRNAs) is predictive of response to TKIs and prognosis for patients with metastatic renal cell carcinoma (mRCC).

Study Better Characterizes Immunotherapy-related Skin Toxicities

By

Patients receiving PD-1 or PD-L1 antibodies exhibited papular and nodular eruptions with scale, as well as mucosal lesions with lichenoid features, that were typically manageable with topical steroid treatment.

Comparative Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis

Comparative Efficacy and Safety of Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-analysis

[Oncotargets and Therapy] This research evaluates the comparative efficacy and safety of axitinib and sorafenib for the treatment of metastatic renal cell carcinoma.

Surgery Improves Survival in Metastatic Kidney Cancer, But Is Little Used

By

Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only approximately 3 in 10 such patients undergo the procedure.

Genetic Differences Explain Survival Disparity in African Americans With Kidney Cancer

By

Several genetic differences uncovered in an analysis of data from The Cancer Genome Atlas (TCGA) are biologically plausible contributing factors for the worse survival of African American patients with clear cell renal carcinoma, even in the era of targeted therapy.

Adjuvant Sorafenib or Sunitinib Not Effective for Local Kidney Cancer

Adjuvant Sorafenib or Sunitinib Not Effective for Local Kidney Cancer

By

Adjuvant treatment with sorafenib or sunitinib demonstrated no survival benefit in patients with resected local renal cell carcinoma at high risk for disease recurrence.

Tumor Heterogeneity as a Rationale for a Multi-epitope Approach in an Autologous Renal Cell Cancer Tumor Vaccine

Tumor Heterogeneity as a Rationale for a Multi-epitope Approach in an Autologous Renal Cell Cancer Tumor Vaccine

In this study, researchers sought to characterize a panel of 36 tumor-associated antigens and cellular marker proteins from tumor material of 133 patients with renal cell carcinoma who underwent radical neprhectomy.

Progression-free Survival in Advanced Renal Cell Carcinoma Is Improved With Cabozantinib

By

Findings of the randomized, phase 3 METEOR trial demonstrate progression-free survival in patients with advanced renal cell carcinoma is improved with cabozantinib compared with everolimus.

Study Evaluates Effect of Everolimus-induced Stomatitis

Study Evaluates Effect of Everolimus-induced Stomatitis

By

Everolimus-induced stomatitis did not negatively affect progression-free survival in patients with various types of cancer, such as breast cancer and renal cell carcinoma.

ASCO: Cabozantinib Increases Progression-Free Survival in RCC

ASCO: Cabozantinib Increases Progression-Free Survival in RCC

Improvements to progression-free survival (PFS) seen across patient subgroups treated with cabozantinib.

Nivolumab  Now FDA Approved for Advanced RCC

Nivolumab Now FDA Approved for Advanced RCC

This newly approved drug operates by targeting the PD-1/PD-L1 cellular pathway.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs